Peri-foci Adipose-derived Stem Cells Promote Chemoresistance in Breast Cancer

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2017 Jul 29

PMID 28750689

Citations 26

Authors

Wei-Lan Yeh

Cheng-Fang Tsai

Dar-Ren Chen

Affiliations

Soon will be listed here.

Abstract

Background: Mesenchymal stem cells in tumor microenvironment can influence therapeutic responses in various types of cancers. For triple negative breast cancer, chemotherapy remains the mainstay of standard treatment. Our aim was to investigate the correlation between human adipose-derived stem cells (hAdSCs) and chemoresistance in triple negative breast cancer.

Method: Conditioned medium was collected from hAdSCs, which was isolated from breast cancer patients who had had breast mastectomy. The expression of selected CD markers was evaluated by flow cytometry to characterize hAdSCs. By array analyses of the secreted cytokines and chemokines of hAdSCs, we identified CXCL1 that mediated doxorubicin resistance and the expression of ATP-binding cassette transporters ABCG2 in TNBC. By microRNA microarray, the association between hAdSC-mediated doxorubicin resistance in TNBC was also revealed.

Results: Conditioned medium collected from hAdSCs elicited doxorubicin resistance and enhanced the expression of ABCG2, which is a transporter responsible for the efflux of doxorubicin. CXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.

Conclusions: Our findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer. These findings provide a better understanding of the importance of adipose-derived stem cells in breast cancer microenvironment regarding to the development of chemoresistance and reveal the potential of discovering novel therapeutic strategies to overcome drug resistance in TNBC.

Citing Articles

Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer.

Marchio V, Augimeri G, Morelli C, Vivacqua A, Giordano C, Catalano S Cell Mol Biol Lett. 2025; 30(1):11.

PMID: 39863855 PMC: 11762563. DOI: 10.1186/s11658-025-00694-x.

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.

Exploring the multifaceted role of obesity in breast cancer progression.

Kakkat S, Suman P, Turbat-Herrera E, Singh S, Chakroborty D, Sarkar C Front Cell Dev Biol. 2024; 12():1408844.

PMID: 39040042 PMC: 11260727. DOI: 10.3389/fcell.2024.1408844.

The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update.

Yan L, Lau A, Xu Y Epigenomics. 2024; .

PMID: 38639712 PMC: 11160456. DOI: 10.2217/epi-2023-0430.

The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.

Zhang L Cell Transplant. 2023; 32:9636897231220073.

PMID: 38135917 DOI: 10.1177/09636897231220073.

References

Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C . MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med (Berl). 2011; 89(10):1037-50. DOI: 10.1007/s00109-011-0775-x. View

Dwyer R, Potter-Beirne S, Harrington K, Lowery A, Hennessy E, Murphy J . Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007; 13(17):5020-7. DOI: 10.1158/1078-0432.CCR-07-0731. View

Luo J, Ok Lee S, Liang L, Huang C, Li L, Wen S . Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. 2013; 33(21):2768-78. DOI: 10.1038/onc.2013.233. View

Jones V, Huang R, Chen L, Chen Z, Fu L, Huang R . Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim Biophys Acta. 2016; 1865(2):255-65. DOI: 10.1016/j.bbcan.2016.03.005. View

Klopp A, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M . Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2011; 18(3):771-82. PMC: 3481843. DOI: 10.1158/1078-0432.CCR-11-1916. View

Arshad Z, Karmen L, Choudhary R, Smith J, Branford O, Brindley D . Cell assisted lipotransfer in breast augmentation and reconstruction: A systematic review of safety, efficacy, use of patient reported outcomes and study quality. JPRAS Open. 2017; 10:5-20. PMC: 5193151. DOI: 10.1016/j.jpra.2016.08.004. View

Huh J, Kim T, Kim K, Song J, Jung Y, Jeong J . Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013; 109(2):452-61. PMC: 3721386. DOI: 10.1038/bjc.2013.305. View

Ridge S, Sullivan F, Glynn S . Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017; 16(1):31. PMC: 5286812. DOI: 10.1186/s12943-017-0597-8. View

McMillin D, Negri J, Mitsiades C . The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 2013; 12(3):217-28. DOI: 10.1038/nrd3870. View

10.

Zhang W, Huang P . Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther. 2010; 11(2):150-6. PMC: 3230306. DOI: 10.4161/cbt.11.2.14623. View

11.

Balkwill F, Capasso M, Hagemann T . The tumor microenvironment at a glance. J Cell Sci. 2013; 125(Pt 23):5591-6. DOI: 10.1242/jcs.116392. View

12.

Shi M, Liu Z, Wang F . Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 2011; 164(1):1-8. PMC: 3074211. DOI: 10.1111/j.1365-2249.2011.04327.x. View

13.

Bertolini F, Petit J, Kolonin M . Stem cells from adipose tissue and breast cancer: hype, risks and hope. Br J Cancer. 2015; 112(3):419-23. PMC: 4453662. DOI: 10.1038/bjc.2014.657. View

14.

Meads M, Gatenby R, Dalton W . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-74. DOI: 10.1038/nrc2714. View

15.

Freese K, Kokai L, Edwards R, Philips B, Sheikh M, Kelley J . Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. Cancer Res. 2015; 75(7):1161-8. DOI: 10.1158/0008-5472.CAN-14-2744. View

16.

Sasaki Y, Miki Y, Hirakawa H, Onodera Y, Takagi K, Akahira J . Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: comparison with normal breast and breast carcinoma. Cancer Sci. 2010; 101(10):2286-92. PMC: 11159500. DOI: 10.1111/j.1349-7006.2010.01673.x. View

17.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

18.

Rhee K, Lee J, Eom Y . Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression. Int J Mol Sci. 2015; 16(12):30015-33. PMC: 4691158. DOI: 10.3390/ijms161226215. View

19.

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

20.

Suga H, Matsumoto D, Inoue K, Shigeura T, Eto H, Aoi N . Numerical measurement of viable and nonviable adipocytes and other cellular components in aspirated fat tissue. Plast Reconstr Surg. 2008; 122(1):103-114. DOI: 10.1097/PRS.0b013e31817742ed. View